After 24 weeks, the patients who received dapagliflozin had better control of blood sugar and had lost more weight than patients who received placebo. The patients who received dapagliflozin were also receiving lower doses of insulin at the end of the trial than those who had received placebo. However, more episodes of low blood sugar occurred in patients receiving dapagliflozin than those receiving placebo. In addition, dapagliflozin causes sugar to accumulate in the urine, which raised concern that it might increase genital infections. An increase in genital infections was reported in the patients who received dapagliflozin, although these infections responded to antibiotic treatment.